Liquid biopsy may unlock genetic secrets of brain AVMs
NCT ID NCT07103304
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will analyze blood samples from the drainage vein of brain arteriovenous malformations (AVMs) in 16 adults undergoing embolization. The goal is to identify genetic mutations that may drive these abnormal vessels. Understanding these mutations could pave the way for future targeted drug treatments, but this research is purely observational and does not test any therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward targeted drug therapies for brain arteriovenous malformations, potentially reducing the need for invasive procedures.
- What could go wrong
- This is a very small, early-stage observational study (16 participants) that only looks for genetic mutations. It does not test any treatment, so benefits are uncertain and far off.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 16 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The population consists of patients aged 18 years or older with cAVMs, for whom treatment by venous embolisation was recommended during a multidisciplinary consultation meeting.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Treated for cAVM * Indication for embolisation treatment decided upon during a multidisciplinary team meeting (MDT) * Venous embolisation, with or without arterial embolisation * Patients informed about the study and willing to participate Exclusion Criteria: * Extra-cerebral arteriovenous malformations * Under legal protection measures (guardianship/curatorship, etc.) * Pregnancy * Not eligible for intravenous treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cerebral arteriovenous malformations are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital la Pitié-Salpêtrière
Paris, 75013, France
-
University Hospital of Caen
Caen, 14033, France
-
University Hospital of Rouen
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.